Moreover, evidence is uneven across disorders: while Friedreich’s ataxia and SCA3 have relatively robust and well-powered datasets, many SCAs and rarer hereditary ataxias lack sufficient longitudinal studies, limiting immediate trial readiness. The gene discussed is ATXN3; the disease is Friedreich ataxia.